Rapamycin extends life- and health span because it slows aging
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Making headlines, a thought-provocative paper by Neff, Ehninger and coworkers claims that rapamycin extends life span but has limited effects on aging. How is that possibly possible? And what is aging if not an increase of the probability of death with age. I discuss that the JCI paper actually shows that rapamycin slows aging and also extends lifespan regardless of its direct anti-cancer activities. Aging is, in part, MTOR-driven: a purposeless continuation of developmental growth. Rapamycin affects the same processes in young and old animals: young animals' traits and phenotypes, which continuations become hyperfunctional, harmful and lethal later in life.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2013) · Cell · doi:10.1016/j.cell.2013.05.039 · Cited by 14,982
mTOR: from growth signal integration to cancer, diabetes and ageing
Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941 · cited 1×
“MTOR is involved in most age-related diseases and rapamycin prevents them in mammals [64, 110-123] and slows down aging [81, 124-127].”
BackgroundRapamycin fed late in life extends lifespan in genetically heterogeneous mice
Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., Flurkey, K., Nadon, N. L., Wilkinson, J. E., Frenkel, K., Carter, C. S., et al. (2009) · Nature · doi:10.1038/nature08221 · Cited by 3,766
Extending Healthy Life Span—From Yeast to Humans
Fontana, L., Partridge, L., & Longo, V. D. (2010) · Science · doi:10.1126/science.1172539 · Cited by 3,023 · cited 1×
“Most elderly humans die from agerelated diseases [4-10], which are also called “natural causes”, if a precise diagnosis is unnecessary.”
BackgroundSenescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors
Campisi, J. (2005) · Cell · doi:10.1016/j.cell.2005.02.003 · Cited by 2,379 · cited 1×
“Also, senescence of normal cells creates cancer-promoting microenvironment [96-103].”
BackgroundRavikumar, B., Vacher, C., Berger, Z., Davies, J. E., Luo, S., Oroz, L. G., Scaravilli, F., Easton, D. F., Duden, R., O'Kane, C. J., et al. (2004) · Nature Genetics · doi:10.1038/ng1362 · Cited by 2,347 · cited 1×
“MTOR is involved in most age-related diseases and rapamycin prevents them in mammals [64, 110-123] and slows down aging [81, 124-127].”
BackgroundmTOR is a key modulator of ageing and age-related disease
Johnson, S. C., Rabinovitch, P. S., & Kaeberlein, M. (2013) · Nature · doi:10.1038/nature11861 · Cited by 1,676
mTOR Regulation and Therapeutic Rejuvenation of Aging Hematopoietic Stem Cells
Chen, C., Liu, Y., Liu, Y., & Zheng, P. (2009) · Science Signaling · doi:10.1126/scisignal.2000559 · Cited by 680
Parrinello, S., Coppe, J.-P., Krtolica, A., & Campisi, J. (2005) · Journal of Cell Science · doi:10.1242/jcs.01635 · Cited by 631 · cited 1×
“Also, senescence of normal cells creates cancer-promoting microenvironment [96-103].”
BackgroundJNK Activity in Somatic Stem Cells Causes Loss of Tissue Homeostasis in the Aging Drosophila Gut
Biteau, B., Hochmuth, C. E., & Jasper, H. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2008.07.024 · Cited by 583
Sarkar, S., Ravikumar, B., Floto, R. A., & Rubinsztein, D. C. (2009) · Cell Death & Differentiation · doi:10.1038/cdd.2008.110 · Cited by 578
Genome sequencing reveals insights into physiology and longevity of the naked mole rat
Kim, E. B., Fang, X., Fushan, A. A., Huang, Z., Lobanov, A. V., Han, L., Marino, S. M., Sun, X., Turanov, A. A., Yang, P., et al. (2011) · Nature · doi:10.1038/nature10533 · Cited by 576
Sestrin as a feedback inhibitor of TOR that prevents age-related pathologies
Lee, J. H., Budanov, A. V., Park, E. J., Birse, R., Kim, T. E., Perkins, G. A., Ocorr, K., Ellisman, M. H., Bodmer, R., Bier, E., et al. (2010) · Science · doi:10.1126/science.1182228 · Cited by 570
Liu, D., & Hornsby, P. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3452 · Cited by 499
Dazert, E., & Hall, M. N. (2011) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2011.09.003 · Cited by 460 · cited 1×
“MTOR is involved in most age-related diseases and rapamycin prevents them in mammals [64, 110-123] and slows down aging [81, 124-127].”
BackgroundBavik, C., Coleman, I., Dean, J. P., Knudsen, B., Plymate, S., & Nelson, P. S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1716 · Cited by 453 · cited 1×
“Also, senescence of normal cells creates cancer-promoting microenvironment [96-103].”
BackgroundRapamycin decelerates cellular senescence
Demidenko, Z. N., Zubova, S. G., Bukreeva, E. I., Pospelov, V. A., Pospelova, T. V., & Blagosklonny, M. V. (2009) · Cell Cycle · doi:10.4161/cc.8.12.8606 · Cited by 391
Self-citationRapamycin extends murine lifespan but has limited effects on aging
Neff, F., Flores-Dominguez, D., Ryan, D. P., Horsch, M., Schröder, S., Adler, T., Afonso, L. C., Aguilar-Pimentel, J. A., Becker, L., Garrett, L., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67674 · Cited by 374
Ramos, F. J., Chen, S. C., Garelick, M. G., Dai, D.-F., Liao, C.-Y., Schreiber, K. H., MacKay, V. L., An, E. H., Strong, R., Ladiges, W. C., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003802 · Cited by 349
Anisimov, V. N., Berstein, L. M., Popovich, I. G., Zabezhinski, M. A., Egormin, P. A., Piskunova, T. S., Semenchenko, A. V., Tyndyk, M. L., Yurova, M. N., Kovalenko, I. G., et al. (2011) · Aging · doi:10.18632/aging.100273 · Cited by 285
Iglesias-Bartolome, R., Patel, V., Cotrim, A., Leelahavanichkul, K., Molinolo, A. A., Mitchell, J. B., & Gutkind, J. S. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2012.06.007 · Cited by 284 · cited 2×
“MTOR-driven geroconversion is a conversion from quiescence to senescence [40-59].”
BackgroundThe choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway.
Korotchkina, L. G., Leontieva, O. V., Bukreeva, E. I., Demidenko, Z. N., Gudkov, A. V., & Blagosklonny, M. V. (2010) · Aging · doi:10.18632/aging.100160 · Cited by 278
Self-citationParadoxical suppression of cellular senescence by p53
Demidenko, Z. N., Korotchkina, L. G., Gudkov, A. V., & Blagosklonny, M. V. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002298107 · Cited by 273
Self-citationMutations That Increase the Life Span of C. elegans Inhibit Tumor Growth
Pinkston, J. M., Garigan, D., Hansen, M., & Kenyon, C. (2006) · Science · doi:10.1126/science.1121908 · Cited by 242
Wang, C.-Y., Kim, H.-H., Hiroi, Y., Sawada, N., Salomone, S., Benjamin, L. E., Walsh, K., Moskowitz, M. A., & Liao, J. K. (2009) · Science Signaling · doi:10.1126/scisignal.2000143 · Cited by 177
Hypoxia suppresses conversion from proliferative arrest to cellular senescence
Leontieva, O. V., Natarajan, V., Demidenko, Z. N., Burdelya, L. G., Gudkov, A. V., & Blagosklonny, M. V. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205690109 · Cited by 169 · cited 1×
“MTOR-driven geroconversion is a conversion from quiescence to senescence [40-59].”
BackgroundSelf-citationRevisiting the antagonistic pleiotropy theory of aging: TOR-driven program and quasi-program
Blagosklonny, M. V. (2010) · Cell Cycle · doi:10.4161/cc.9.16.13120 · Cited by 160
Self-citationCell senescence and hypermitogenic arrest
Blagosklonny, M. V. (2003) · The EMBO Reports · doi:10.1038/sj.embor.embor806 · Cited by 156 · cited 1×
“MTOR-driven geroconversion is a conversion from quiescence to senescence [40-59].”
BackgroundSelf-citationCaveolin-1 and Accelerated Host Aging in the Breast Tumor Microenvironment
Mercier, I., Camacho, J., Titchen, K., Gonzales, D. M., Quann, K., Bryant, K. G., Molchansky, A., Milliman, J. N., Whitaker-Menezes, D., Sotgia, F., et al. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.03.017 · Cited by 96 · cited 2×
“MTOR-driven geroconversion is a conversion from quiescence to senescence [40-59].”
BackgroundSelf-citationTOR-Driven Aging: Speeding Car Without Brakes
Blagosklonny, M. V. (2009) · Cell Cycle · doi:10.4161/cc.8.24.10310 · Cited by 95 · cited 1×
“In other words, aging is a quasi-program (not a program): an unintended and purposeless continuation of developmental programs, which are not switched off upon their completion [64-67], causing age-related diseases.”
BackgroundSelf-citationDurán, R. V., & Hall, M. N. (2012) · Cell Cycle · doi:10.4161/cc.22632 · Cited by 77
Cited by
Rapamycin: one drug, many effects
Li, J., Kim, S. G., & Blenis, J. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.01.001 · Cited by 1,287
Age and Age-Related Diseases: Role of Inflammation Triggers and Cytokines
Rea, I. M., Gibson, D. S., McGilligan, V., McNerlan, S. E., Alexander, H. D., & Ross, O. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00586 · Cited by 1,267
Long live FOXO : unraveling the role of FOXO proteins in aging and longevity
Martins, R., Lithgow, G. J., & Link, W. (2016) · Aging Cell · doi:10.1111/acel.12427 · Cited by 720
Mouse models of ageing and their relevance to disease
Kõks, S., Dogan, S., Tuna, B. G., González-Navarro, H., Potter, P., & Vandenbroucke, R. E. (2016) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2016.10.001 · Cited by 125
“This interpretation has been challenged Blagosklonny, 2013).”
Role of senescence in the chronic health consequences of COVID-19
Wissler Gerdes, E. O., Vanichkachorn, G., Verdoorn, B. P., Hanson, G. J., Joshi, A. Y., Murad, M. H., Rizza, S. A., Hurt, R. T., Tchkonia, T., & Kirkland, J. L. (2022) · Translational Research · doi:10.1016/j.trsl.2021.10.003 · Cited by 38
“Rapamycin has been approved to treat lymphangioleiomyomatosis, an invasive lung disease(134) and has been shown to extend healthspan and lifespan in mice.(133,135) Some have suggested that long-term preventative usage of Rapamycin might decrease COVID-19 vulnerability and mortality in the elderly.”
Metadata
- Authors
- Blagosklonny, M. V.
- Venue
- Aging
- Publisher
- Impact Journals, LLC
- Published
- 2013-08-11
- Volume
- 5
- Issue
- 8
- Pages
- 592-598
- ISSN
- 1945-4589 (ISSN-L)
- OpenAlex
- W1566357531
- Cited by
- 81
- References
- 31
- FWCI
- 4.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.